Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital

Key Points

• Lifesci Capital has lowered its Q1 2026 earnings estimate for Zymeworks, now predicting $0.47 per share compared to a previous estimate of $0.49.
• Zymeworks reported revenue of $48.73 million for the recent quarter, significantly exceeding analyst estimates of $17.18 million, and had a 153.2% increase in revenue compared to the same quarter last year.
• Insider activity has seen Ecor1 Capital acquire 49,502 shares at an average cost of $11.43 per share, increasing their ownership in Zymeworks.

Zymeworks Inc. (NYSE:ZYME - Free Report) - Lifesci Capital cut their Q1 2026 EPS estimates for Zymeworks in a research note issued to investors on Thursday, August 7th. Lifesci Capital analyst C. Zhu now expects that the company will post earnings of $0.47 per share for the quarter, down from their previous forecast of $0.49. The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share.

Other equities analysts have also issued research reports about the stock. HC Wainwright restated a "neutral" rating and set a $13.00 price target on shares of Zymeworks in a research report on Thursday, July 3rd. Citigroup upped their price target on shares of Zymeworks from $19.00 to $22.00 and gave the stock a "buy" rating in a research report on Monday. TD Securities started coverage on shares of Zymeworks in a research report on Tuesday, May 20th. They set a "buy" rating for the company. Finally, TD Cowen started coverage on shares of Zymeworks in a research report on Tuesday, May 20th. They set a "buy" rating for the company. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $21.43.

Zymeworks Stock Performance

Shares of Zymeworks stock traded up $0.00 during trading on Monday, hitting $14.30. 61,904 shares of the stock were exchanged, compared to its average volume of 533,545. The stock's fifty day moving average is $13.03 and its 200 day moving average is $12.66. The stock has a market cap of $1.07 billion, a PE ratio of -9.56 and a beta of 1.26. Zymeworks has a 12 month low of $9.03 and a 12 month high of $17.70.

Zymeworks (NYSE:ZYME - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.55. The firm had revenue of $48.73 million during the quarter, compared to analyst estimates of $17.18 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The firm's revenue for the quarter was up 153.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.49) earnings per share.

Institutional Investors Weigh In On Zymeworks

Several institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. acquired a new stake in Zymeworks in the 4th quarter valued at about $585,000. JPMorgan Chase & Co. lifted its holdings in Zymeworks by 185.1% in the 4th quarter. JPMorgan Chase & Co. now owns 111,983 shares of the company's stock valued at $1,639,000 after acquiring an additional 72,703 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Zymeworks by 1.9% in the 4th quarter. Federated Hermes Inc. now owns 181,626 shares of the company's stock valued at $2,659,000 after acquiring an additional 3,367 shares during the last quarter. Legal & General Group Plc lifted its holdings in Zymeworks by 5.8% in the 4th quarter. Legal & General Group Plc now owns 47,082 shares of the company's stock valued at $689,000 after acquiring an additional 2,590 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Zymeworks by 54.8% in the 4th quarter. Renaissance Technologies LLC now owns 285,700 shares of the company's stock valued at $4,183,000 after acquiring an additional 101,100 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.

Insiders Place Their Bets

In related news, Director Ecor1 Capital, Llc acquired 5,919 shares of Zymeworks stock in a transaction that occurred on Monday, May 19th. The stock was acquired at an average price of $11.78 per share, with a total value of $69,725.82. Following the completion of the acquisition, the director directly owned 17,883,908 shares of the company's stock, valued at $210,672,436.24. This trade represents a 0.03% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.92% of the stock is owned by insiders.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.